SDC1 and neoplasm: SSTNIGF-1R (or SSTN92-119) mimics the docking site of αvβ3 and αvβ5 integrins and IGF-1R to prevent their interaction with CD138, thereby competitively disrupting the ternary complex and smothering pro-tumor pathways (121, 176, 177).